

# Magi Farre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1599587/publications.pdf>

Version: 2024-02-01

185  
papers

8,494  
citations

43973

48  
h-index

54797

84  
g-index

194  
all docs

194  
docs citations

194  
times ranked

9301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nocebo Response in Attention Deficit Hyperactivity Disorder: Meta-Analysis and Meta-Regression of 105 Randomized Clinical Trials. <i>Journal of Attention Disorders</i> , 2022, 26, 1412-1421.	1.5	1
2	Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World. <i>Value in Health</i> , 2022, 25, 770-772.	0.1	5
3	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 278-288.	5.2	61
4	Abuse Potential of Cathinones in Humans: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1004.	1.0	13
5	BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression. <i>Frontiers in Psychiatry</i> , 2022, 13, 836771.	1.3	2
6	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona. <i>European Addiction Research</i> , 2022, 28, 323-330.	1.3	3
7	Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder. <i>Biomedicines</i> , 2022, 10, 947.	1.4	5
8	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. <i>Biology</i> , 2022, 11, 645.	1.3	2
9	Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 4038.	1.0	6
10	Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. <i>Phytotherapy Research</i> , 2021, 35, 1646-1657.	2.8	13
11	UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis. <i>Talanta</i> , 2021, 223, 121772.	2.9	17
12	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 417-427.	13.9	179
13	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108616.	1.1	2
14	Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans. <i>Pharmaceuticals</i> , 2021, 14, 100.	1.7	14
15	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 625610.	1.6	7
16	Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users. <i>Biology</i> , 2021, 10, 257.	1.3	10
17	Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4000.	1.8	19
18	Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice. <i>Psychopharmacology</i> , 2021, 238, 1923-1936.	1.5	1

#	ARTICLE	IF	CITATIONS
19	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 708372.	1.5	7
20	Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 705643.	1.6	8
21	A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure. <i>Biology</i> , 2021, 10, 788.	1.3	10
22	Drug-Related Deaths in a Tertiary Hospital: Characteristics of Spontaneously Reported Cases and Comparison to Cases Detected from a Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4053.	1.0	3
23	Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse. <i>Pharmaceutics</i> , 2021, 13, 1532.	2.0	7
24	Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. <i>Pharmaceutics</i> , 2021, 14, 59.	1.7	11
25	Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital. <i>Journal of Clinical Medicine</i> , 2021, 10, 5531.	1.0	2
26	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. <i>Clinical Nutrition</i> , 2020, 39, 378-387.	2.3	16
27	Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. <i>Talanta</i> , 2020, 209, 120537.	2.9	36
28	UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers. <i>Medicina (Lithuania)</i> , 2020, 56, 408.	0.8	13
29	Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis. <i>Pharmaceutics</i> , 2020, 13, 459.	1.7	10
30	Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9414.	1.8	12
31	The Tryptophan System in Cocaine-Induced Depression. <i>Journal of Clinical Medicine</i> , 2020, 9, 4103.	1.0	11
32	Acute Effects of 2C-E in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 233.	1.6	11
33	MDMA interactions with pharmaceuticals and drugs of abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 357-369.	1.5	19
34	Oral Administration of Cannabis and Î”-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. <i>Medicina (Lithuania)</i> , 2020, 56, 309.	0.8	38
35	Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study. <i>Phytotherapy Research</i> , 2020, 34, 1670-1677.	2.8	16
36	LC-MS/MS method for the quantification of new psychoactive substances and evaluation of their urinary detection in humans for doping control analysis. <i>Drug Testing and Analysis</i> , 2020, 12, 785-797.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Effects of cannabis exposure in the prenatal and adolescent periods: Preclinical and clinical studies in both sexes. <i>Frontiers in Neuroendocrinology</i> , 2020, 57, 100841.	2.5	25
38	Dietary inflammatory index and all-cause mortality in large cohorts: The SUN and PREDIMED studies. <i>Clinical Nutrition</i> , 2019, 38, 1221-1231.	2.3	87
39	Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 131.	1.6	9
40	Meconium Biomarkers of Prenatal Alcohol Exposure. , 2019, , 585-594.		0
41	Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. <i>PLoS ONE</i> , 2019, 14, e0213791.	1.1	18
42	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , 2019, 236, 2677-2685.	1.5	26
43	Respuesta. <i>Medicina Clínica</i> , 2019, 152, 79-80.	0.3	0
44	Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotonergic Effects, and Impact of <i>CYP2D6</i> Genetic Variation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 596-604.	2.3	17
45	Short- and medium-term impact of bariatric surgery on the activities of <i>CYP2D6</i> , <i>CYP3A4</i> , <i>CYP2C9</i> , and <i>CYP1A2</i> in morbid obesity. <i>Scientific Reports</i> , 2019, 9, 20405.	1.6	25
46	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , 2019, 33, 347-354.	2.0	21
47	Potential Use of Ayahuasca in Grief Therapy. <i>Omega: Journal of Death and Dying</i> , 2019, 79, 260-285.	0.7	21
48	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , 2019, 10, 943.	1.3	80
49	Mephedrone and Alcohol Interactions in Humans. <i>Frontiers in Pharmacology</i> , 2019, 10, 1588.	1.6	21
50	Ethics in clinical research: Contributions of the new version of the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 282-285.	0.1	1
51	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. <i>Scientific Reports</i> , 2018, 8, 1061.	1.6	13
52	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 183-195.	1.5	15
53	Ética de la investigación clínica: aportaciones de la nueva versión de las recomendaciones del Council for International Organizations of Medical Sciences. <i>Medicina Clínica</i> , 2018, 150, 282-285.	0.3	4
54	The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis. <i>Addictive Behaviors</i> , 2018, 79, 52-60.	1.7	39

#	ARTICLE	IF	CITATIONS
55	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <i>Psychopharmacology</i> , 2018, 235, 709-717.	1.5	6
56	Drug-related deaths in hospital inpatients: A retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 542-552.	1.1	48
57	Drug Interactions With New Synthetic Opioids. <i>Frontiers in Pharmacology</i> , 2018, 9, 1145.	1.6	42
58	Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis. <i>JAMA Network Open</i> , 2018, 1, e183485.	2.8	57
59	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. <i>Drug and Alcohol Dependence</i> , 2018, 188, 180-186.	1.6	6
60	Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 206.	1.6	38
61	Cannabinoids: from pot to lab. <i>International Journal of Medical Sciences</i> , 2018, 15, 1286-1295.	1.1	53
62	Pacientes con trastorno por uso de alcohol: resultados iniciales de un registro multicéntrico en la Red de Trastornos Adictivos-RTA. <i>Estudio CohRTA. Revista De Psicología De La Salud</i> , 2018, 30, 292.	0.2	1
63	Mephedrone Concentrations in Cases of Clinical Intoxication. <i>Current Pharmaceutical Design</i> , 2018, 23, 5511-5522.	0.9	66
64	GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. <i>Journal of Analytical Toxicology</i> , 2017, 41, 100-106.	1.7	19
65	Effect of olive oil phenolic compounds on the expression of blood pressure-related genes in healthy individuals. <i>European Journal of Nutrition</i> , 2017, 56, 663-670.	1.8	46
66	Effect of virgin olive oil and thyme phenolic compounds on blood lipid profile: implications of human gut microbiota. <i>European Journal of Nutrition</i> , 2017, 56, 119-131.	4.6	93
67	Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. <i>Addiction Biology</i> , 2017, 22, 1036-1047.	1.4	38
68	Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. <i>Obesity Surgery</i> , 2017, 27, 3194-3201.	1.1	25
69	Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 297-305.	1.0	61
70	Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". <i>Obesity Surgery</i> , 2017, 27, 3006-3007.	1.1	0
71	Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. <i>AAPS Journal</i> , 2017, 19, 1767-1778.	2.2	31
72	Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2017, 11, 34-39.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Patterns of use and toxicity of new para-halogenated substituted cathinones: 4- <i>CMC</i> (clephedrone), 4- <i>CEC</i> (4-chloroethcatinone) and 4- <i>BMC</i> (brepheдрone). <i>Human Psychopharmacology</i> , 2017, 32, e2621.	0.7	29
74	Non-Linear Formation of EtG and FAEs after Controlled Administration of Low to Moderate Doses of Ethanol. <i>Alcohol and Alcoholism</i> , 2017, 52, 587-594.	0.9	6
75	Corrigendum to "Genetic and protein biomarkers in blood for the improved detection of GH abuse". <i>Pharm. Biomed. Anal.</i> 128 (2016) 111-118, doi: 10.1016/j.jpba.2016.05.022.]. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 385.	1.4	0
76	Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. <i>Drug Testing and Analysis</i> , 2017, 9, 1011-1016.	1.6	15
77	The hidden web and the fentanyl problem: Detection of ocfentaniil as an adulterant in heroin. <i>International Journal of Drug Policy</i> , 2017, 40, 78-83.	1.6	64
78	Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 415-423.	1.4	14
79	A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (11-Imidazoline Receptor). <i>Frontiers in Psychiatry</i> , 2017, 8, 258.	1.3	6
80	Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 554-566.	0.8	29
81	Concurrent Use of Cannabis and Alcohol: Neuropsychiatric Effect Consequences. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 592-597.	0.8	6
82	Alcohol Consumption during Pregnancy: Analysis of Two Direct Metabolites of Ethanol in Meconium. <i>International Journal of Molecular Sciences</i> , 2016, 17, 417.	1.8	6
83	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 313-331.	0.8	28
84	PCP analogues in samples of Barcelona from 2009 to 2015. <i>European Psychiatry</i> , 2016, 33, S117-S117.	0.1	1
85	Genetic and protein biomarkers in blood for the improved detection of GH abuse. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 128, 111-118.	1.4	14
86	Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol. <i>Drug Metabolism Reviews</i> , 2016, 48, 218-236.	1.5	121
87	The synthetic cannabinoids: JWH, four years of analysis. <i>European Psychiatry</i> , 2016, 33, S115-S116.	0.1	2
88	Human Pharmacology of Mephedrone in Comparison with MDMA. <i>Neuropsychopharmacology</i> , 2016, 41, 2704-2713.	2.8	132
89	Determination of Recent Growth Hormone Abuse Using a Single Dried Blood Spot. <i>Clinical Chemistry</i> , 2016, 62, 1353-1360.	1.5	22
90	Neurocognitive performance following acute mephedrone administration, with and without alcohol. <i>Journal of Psychopharmacology</i> , 2016, 30, 1305-1312.	2.0	22

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 801-810.	4.9	227
92	“Flakka”: an Emerging Trend Or a Mass Media Phenomenon? Presence of alpha-pvp in Samples Submitted To a Drug Checking Facility. <i>European Psychiatry</i> , 2016, 33, S442-S442.	0.1	2
93	Analysis of free hydroxytyrosol in human plasma following the administration of olive oil. <i>Journal of Chromatography A</i> , 2016, 1437, 183-190.	1.8	42
94	Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 89-98.	1.0	25
95	Facial emotion processing in patients with social anxiety disorder and Williams’s “Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 182-191.	1.4	20
96	Complementary phenol-enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double-blind, crossover, controlled trial. The VOHF study. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 1758-1770.	1.5	43
97	Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma A $\beta$ 242 Concentrations in Down Syndrome Young Adults. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 301.	1.0	23
98	Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. <i>International Journal of Medical Sciences</i> , 2015, 12, 811-824.	1.1	116
99	A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. <i>Frontiers in Psychology</i> , 2015, 6, 708.	1.1	53
100	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	28
101	In vitro study of the apical microleakage with resilon root canal filling using different final endodontic irrigants. <i>Journal of Clinical and Experimental Dentistry</i> , 2015, 7, e212-e217.	0.5	7
102	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart. <i>European Neuropsychopharmacology</i> , 2015, 25, 1637-1649.	0.3	24
103	Mass Spectrometric Evaluation of Mephedrone In Vivo Human Metabolism: Identification of Phase I and Phase II Metabolites, Including a Novel Succinyl Conjugate. <i>Drug Metabolism and Disposition</i> , 2015, 43, 248-257.	1.7	73
104	Detection and characterization of betamethasone metabolites in human urine by LC-MS/MS. <i>Drug Testing and Analysis</i> , 2015, 7, 663-672.	1.6	19
105	Moderate consumption of wine, through both its phenolic compounds and alcohol content, promotes hydroxytyrosol endogenous generation in humans. A randomized controlled trial. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 1213-1216.	1.5	32
106	Conditioned Subjective Responses to Socially Relevant Stimuli in Social Anxiety Disorder and Subclinical Social Anxiety. <i>Clinical Psychology and Psychotherapy</i> , 2015, 22, 221-231.	1.4	14
107	Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial. <i>Journal of Nutrition</i> , 2015, 145, 1692-1697.	1.3	73
108	Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 6946-6953.	2.4	22



#	ARTICLE	IF	CITATIONS
109	Untargeted Metabolomics in Doping Control: Detection of New Markers of Testosterone Misuse by Ultrahigh Performance Liquid Chromatography Coupled to High-Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2015, 87, 8373-8380.	3.2	39
110	Fit-for-Purpose Radio Receptor Assay for the Determination of Growth Hormone Secretagogues in Urine. <i>Journal of Biomolecular Screening</i> , 2015, 20, 1268-1276.	2.6	6
111	Ethanol induces hydroxytyrosol formation in humans. <i>Pharmacological Research</i> , 2015, 95-96, 27-33.	3.1	20
112	Conditioned Fear Acquisition and Generalization in Generalized Anxiety Disorder. <i>Behavior Therapy</i> , 2015, 46, 627-639.	1.3	58
113	Potential Role of Olive Oil Phenolic Compounds in the Prevention of Neurodegenerative Diseases. <i>Molecules</i> , 2015, 20, 4655-4680.	1.7	181
114	Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. <i>Psychopharmacology</i> , 2015, 232, 1921-1929.	1.5	11
115	Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. <i>Cortex</i> , 2015, 64, 148-156.	1.1	64
116	Addiction to Hallucinogens, Dissociatives, Designer Drugs and "Legal Highs", 2015, , 567-596.		2
117	No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation. <i>PLoS ONE</i> , 2014, 9, e100719.	1.1	72
118	The Definition of Placebo in the Informed Consent Forms of Clinical Trials. <i>PLoS ONE</i> , 2014, 9, e113654.	1.1	16
119	Bilastine vs. hydroxyzine: occupation of brain histamine H <sub>1</sub> receptors evaluated by positron emission tomography in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 970-980.	1.1	52
120	Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. <i>Journal of Lipid Research</i> , 2014, 55, 966-977.	2.0	45
121	Modulation of brain structure by catechol-O-methyltransferase Val <sup>158</sup> Met polymorphism in chronic cannabis users. <i>Addiction Biology</i> , 2014, 19, 722-732.	1.4	34
122	Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1829-1839.	0.7	21
123	Emerging drugs in Europe. <i>Current Opinion in Psychiatry</i> , 2014, 27, 243-250.	3.1	48
124	Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects. <i>Addiction Biology</i> , 2014, 19, 272-281.	1.4	41
125	Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 278-288.	1.5	234
126	3,4-Methylenedioxymethamphetamine Induces Gene Expression Changes in Rats Related to Serotonergic and Dopaminergic Systems, But Not to Neurotoxicity. <i>Neurotoxicity Research</i> , 2014, 25, 161-169.	1.3	13



#	ARTICLE	IF	CITATIONS
127	Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. <i>Journal of Psychiatric Research</i> , 2014, 51, 68-78.	1.5	88
128	Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: Initial validation of an imaging protocol for drug discovery. <i>European Neuropsychopharmacology</i> , 2014, 24, 105-116.	0.3	18
129	Determination of free serotonin and its metabolite 5-HIAA in blood human samples with consideration to pre-analytical factors. <i>Biomedical Chromatography</i> , 2014, 28, 1641-1646.	0.8	12
130	Memory and mood during MDMA intoxication, with and without memantine pretreatment. <i>Neuropharmacology</i> , 2014, 87, 198-205.	2.0	28
131	The efficacy of cognitive behavioural therapy and advocacy interventions for women who have experienced intimate partner violence: A systematic review and meta-analysis. <i>Annals of Medicine</i> , 2014, 46, 567-586.	1.5	49
132	Common and distinct neural correlates of facial emotion processing in social anxiety disorder and Williams syndrome: A systematic review and voxel-based meta-analysis of functional resonance imaging studies. <i>Neuropsychologia</i> , 2014, 64, 205-217.	0.7	41
133	Metabolite profiling of olive oil and thyme phenols after a sustained intake of two phenol-enriched olive oils by humans: Identification of compliance markers. <i>Food Research International</i> , 2014, 65, 59-68.	2.9	49
134	ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. <i>European Neuropsychopharmacology</i> , 2014, 24, 420-424.	0.3	10
135	Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1066-1074.	0.8	30
136	Prophylactic Antidepressant Treatment of Interferon-Induced Depression in Chronic Hepatitis C. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e1113-e1121.	1.1	34
137	Consumption of new psychoactive substances in a Spanish sample of research chemical users. <i>Human Psychopharmacology</i> , 2013, 28, 332-340.	0.7	41
138	Efficacy of psychostimulant drugs for amphetamine abuse or dependence. <i>The Cochrane Library</i> , 2013, , CD009695.	1.5	52
139	Dose-dependent metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. <i>Pharmacological Research</i> , 2013, 77, 47-56.	3.1	54
140	Urinary profile of methylprednisolone and its metabolites after oral and topical administrations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 214-221.	1.2	31
141	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2h apart. <i>Psychopharmacology</i> , 2013, 225, 883-893.	1.5	35
142	Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. <i>British Journal of Pharmacology</i> , 2013, 168, 607-617.	2.7	20
143	Bioethical principles, clinical research and popular movies. <i>Medical Education</i> , 2013, 47, 1141-1142.	1.1	5
144	Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers. <i>Current Pharmaceutical Design</i> , 2012, 18, 4966-4979.	0.9	225

#	ARTICLE	IF	CITATIONS
145	Changes in CYP1A2 Activity in Humans after 3,4-Methylenedioxyamphetamine (MDMA, Ecstasy) Administration Using Caffeine as a Probe Drug. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 605-613.	1.1	20
146	MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?. <i>Frontiers in Genetics</i> , 2012, 3, 235.	1.1	72
147	Clinical Pharmacology of 3,4-Methylenedioxyamphetamine (MDMA, "Ecstasy"): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT). <i>PLoS ONE</i> , 2012, 7, e47599.	1.1	48
148	Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 221-226.	2.5	198
149	4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. <i>Journal of Psychopharmacology</i> , 2012, 26, 1026-1035.	2.0	92
150	Surviving life-threatening MDMA (3,4-methylenedioxyamphetamine, ecstasy) toxicity caused by ritonavir (RTV). <i>Intensive Care Medicine</i> , 2012, 38, 1239-1240.	3.9	17
151	Sex Differences in 3,4-Methylenedioxyamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans. <i>Clinical Pharmacokinetics</i> , 2011, 50, 319-329.	1.6	27
152	Author's response to the Letter to the Editor of Tfelt-Hansen. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 645-646.	0.8	0
153	Antioxidant Activities of Hydroxytyrosol Main Metabolites Do Not Contribute to Beneficial Health Effects after Olive Oil Ingestion. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1417-1421.	1.7	51
154	Neurotoxic Thioether Adducts of 3,4-Methylenedioxyamphetamine Identified in Human Urine After Ecstasy Ingestion. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1448-1455.	1.7	30
155	Study of paracetamol 1g oral solution bioavailability. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008, 30, 37.	0.8	8
156	MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder. <i>Journal of Psychoactive Drugs</i> , 2008, 40, 225-236.	1.0	138
157	The Consequences of 3,4-Methylenedioxyamphetamine Induced CYP2D6 Inhibition in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 523-529.	0.7	49
158	Pharmacological Interaction between 3,4-Methylenedioxyamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 954-962.	1.3	93
159	Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. <i>Journal of Psychopharmacology</i> , 2006, 20, 842-849.	2.0	77
160	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 551-554.	0.8	42
161	Efficacy of antidepressants in substance use disorders with and without comorbid depression. <i>Drug and Alcohol Dependence</i> , 2005, 78, 1-22.	1.6	226
162	Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxyamphetamine Disposition in Humans. <i>Clinical Pharmacokinetics</i> , 2005, 44, 649-660.	1.6	57

#	ARTICLE	IF	CITATIONS
163	Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. <i>Psychopharmacology</i> , 2004, 173, 364-375.	1.5	120
164	Putting Clinical Pharmacology in Context: The Use of Popular Movies. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 30-36.	1.0	39
165	Human Pharmacology of MDMA. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 137-144.	1.0	377
166	Hydroxytyrosol Disposition in Humans. <i>Clinical Chemistry</i> , 2003, 49, 945-952.	1.5	266
167	Determination of MDMA and its Metabolites in Blood and Urine by Gas Chromatography-Mass Spectrometry and Analysis of Enantiomers by Capillary Electrophoresis. <i>Journal of Analytical Toxicology</i> , 2002, 26, 157-165.	1.7	98
168	3,4-Methylenedioxyamphetamine (Ecstasy) and Alcohol Interactions in Humans: Psychomotor Performance, Subjective Effects, and Pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 236-244.	1.3	144
169	On-site testing of 3,4-methylenedioxyamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. <i>Clinical Chemistry</i> , 2002, 48, 174-6.	1.5	7
170	Prevalence and Risk of Gingival Enlargement in Patients Treated With Nifedipine. <i>Journal of Periodontology</i> , 2001, 72, 605-611.	1.7	73
171	Usefulness of saliva for measurement of 3,4-methylenedioxyamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. <i>Clinical Chemistry</i> , 2001, 47, 1788-95.	1.5	28
172	Non-linear pharmacokinetics of MDMA (â€œecstasyâ€™) in humans. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 104-109.	1.1	304
173	Pharmacology of MDMA in Humans. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 225-237.	1.8	140
174	Human Pharmacology of 3,4-Methylenedioxyamphetamine ("Ecstasy"): Psychomotor Performance and Subjective Effects. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 455-466.	0.7	185
175	Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxyamphetamine in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 290, 136-45.	1.3	211
176	Abuse liability of flunitrazepam among methadone-maintained patients. <i>Psychopharmacology</i> , 1998, 140, 486-495.	1.5	39
177	Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses. <i>Arzneimittelforschung</i> , 1997, 47, 528-30.	0.5	0
178	Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 283, 164-76.	1.3	92
179	Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1997, 19, 343-50.	0.8	0
180	Gingival Enlargement Induced by Drugs. <i>Drug Safety</i> , 1996, 15, 219-231.	1.4	69

#	ARTICLE	IF	CITATIONS
181	A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. <i>Psychopharmacology</i> , 1996, 125, 1-12.	1.5	26
182	Cross-Reactivity of Stimulants Found in Sports Drug Testing by Two Fluorescence Polarization Immunoassays. <i>Journal of Analytical Toxicology</i> , 1996, 20, 165-170.	1.7	20
183	Sensation seeking amongst healthy volunteers participating in phase I clinical trials.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 405-409.	1.1	17
184	Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). <i>Drug and Alcohol Dependence</i> , 1994, 35, 203-209.	1.6	45
185	Alcohol and cocaine interactions in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1993, 266, 1364-73.	1.3	145